Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 1

Status

Completed 13Unknown 4Terminated 3Withdrawn 1Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 2Sarcoma 1Plasma cell 1Other solid neoplasm 1Head & Neck 1Genitourinary 1Dermatologic 1

Conditions

Hypoxia 2Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Melanoma 1Gastrointestinal Stromal Tumors 1

Interventions

Cisplatin 504Cyclophosphamide 353Radiotherapy 349Carboplatin 347Capecitabine 328Oxaliplatin 319Paclitaxel 316Gemcitabine 315Docetaxel 308Fluorouracil 281apatinib 240Drug Therapy 239Bevacizumab 224camrelizumab 212Etoposide 199Irinotecan 176Doxorubicin 174Dexamethasone 159Leucovorin 158sintilimab 140Pemetrexed 136Cytarabine 136pembrolizumab 135anlotinib 135toripalimab 124S 1 (combination) 119Neoadjuvant Therapy 119Vincristine 118Rituximab 114Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Unknown × Interventional × TH 302 × Clear all
NCT03098160 2017-10-30

Immunotherapy Study of Evofosfamide in Combination With Ipilimumab

Threshold Pharmaceuticals

Phase 1 Unknown
69 enrolled
DermatologicGastrointestinalGenitourinaryHead & Neck

Squamous Cell Carcinoma of Head and Neck, Hypoxia, Melanoma, Pancreatic Neoplasms, Prostatic Neoplasms

NCT01522872 2016-06-02

Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma

Threshold Pharmaceuticals

Phase 1/2 Unknown
98 enrolled
Plasma cell

Hypoxia, Multiple Myeloma, Neoplasms, Plasma Cell

NCT02020226 2016-06-02

A Cardiac Safety Study of TH-302 in Patients With Advanced Solid Tumors

Threshold Pharmaceuticals

Phase 1 Unknown
40 enrolled
Other solid neoplasm

Solid Tumors

NCT01381822 2014-04-21

TH-CR-410

Threshold Pharmaceuticals

Phase 1 Unknown
58 enrolled
GastrointestinalSarcoma

Neuroectodermal Tumors, Primitive, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡